Logo

Revenues and Earnings up for ABI in Q3 of FY2004

Apr 27, 2004

NEW YORK, April 27 (GenomeWeb News) - Applied Biosystems reported increased revenues and earnings for its fiscal year 2004 third quarter today.

 

Revenues for the quarter were $439.6 million, up from $409.4 million during the same quarter last year.

 

Revenues in different product categories were as follows (year-ago revenues in brackets): DNA sequencing $137.5 million ($143.6 million), SDS and other applied genomics $111.6 million ($86.8 million), mass spectrometry $109.4 million ($93.3 million), core DNA synthesis and PCR $50.2 million ($50.7 million), other product lines $30.9 million ($35 million).

 

R&D spending decreased to $57.1 million, from $60 million during the year-ago period.

 

ABI's net earnings for the quarter were $46 million, or $.22 per share, up from $40.1 million, or $.19 per share, during the same period last year.

 

The company, a unit of Applera, did not include its assets in its financial statement.

 

Breaking News
The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.